Paid Clinical Trials Evansville

Discover 39 paid clinical trials in Evansville, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 39

Hintermann H3Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

Recruiting

Sponsor:

DT MedTech, LLC

Location:

Evansville IN, Morrisville NC, Charleston SC, Baltimore MDshow 5 more

Code:

NCT04770870

Conditions

Osteoarthritis Ankle

Post-Traumatic Osteoarthritis of Ankle

Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Accepted

Interventions

Hintermann Series H3 Total Ankle Replacement System

SebetralstatOpen-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Recruiting

PHASE3

Sponsor:

KalVista Pharmaceuticals, Ltd.

Location:

Evansville IN, Saint Louis MO, Birmingham AL, Toledo OHshow 6 more

Code:

NCT06467084

Conditions

Hereditary Angioedema

Eligibility Criteria

Sex: All

Age: 2 - 11

Healthy Volunteers: Not accepted

Interventions

KVD900 75 mg

KVD900 150 mg

KVD900 300 mg

Observational StudyRegistry of the Patient Experience for Carpal Tunnel Release

Recruiting

Sponsor:

Sonex Health, Inc.

Location:

Evansville IN, Lexington KY, Raleigh NC, Foley ALshow 7 more

Code:

NCT06071468

Conditions

Carpal Tunnel Syndrome

CTS

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)

Endocscopic CTR

Open CTR

SPN-812Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Recruiting

Sponsor:

Supernus Pharmaceuticals, Inc.

Location:

Evansville IN, Owensboro KY, Bardstown KY, Cincinnati OHshow 37 more

Code:

NCT04781140

Conditions

Attention-Deficit/Hyperactivity Disorder

Eligibility Criteria

Sex: All

Age: 48 - 69

Healthy Volunteers: Not accepted

Interventions

100mg SPN-812

Placebo

KVD900PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting

PHASE3

Sponsor:

KalVista Pharmaceuticals, Ltd.

Location:

Evansville IN, Saint Louis MO, Cincinnati OH, Toledo OHshow 12 more

Code:

NCT05511922

Conditions

Hereditary Angioedema

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

KVD900 600 mg

Drug: KVD900 300 mg

Nivolumab & IpilimumabA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting

PHASE2

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Evansville IN, Newburgh IN, Carterville IL, Carbondale ILshow 362 more

Code:

NCT02339571

Conditions

Stage III Cutaneous Melanoma AJCC v7

Stage IV Cutaneous Melanoma AJCC v6 and v7

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Echocardiography Test

Ipilimumab

Magnetic Resonance Elastography

Durvalumab & TremelimumabA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Evansville IN, Carterville IL, Nashville TN, Saint Louis MOshow 64 more

Code:

NCT06008093

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

Tremelimumab

Pemetrexed

Pembrolizumab

Carboplatin

AtogepantA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Evansville IN, Nashville TN, Huntsville AL, Little Rock ARshow 14 more

Code:

NCT06810505

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Atogepant

Placebo for Atogepant

Enlicitide DecanoateEnlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Evansville IN, Louisville KY, Hazelwood MO, Lexington KYshow 116 more

Code:

NCT06008756

Conditions

Arteriosclerosis

Hypercholesterolaemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enlicitide Decanoate

Placebo

AbeLacimabStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Recruiting

PHASE3

Sponsor:

Anthos Therapeutics, Inc.

Location:

Evansville IN, Beavercreek OH, Germantown TN, Memphis TNshow 82 more

Code:

NCT05712200

Conditions

Atrial Fibrillation (AF)

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Abelacimab

Placebo

Paid Clinical Trials Evansville

Filter results

Hintermann H3Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

SebetralstatOpen-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Observational StudyRegistry of the Patient Experience for Carpal Tunnel Release

SPN-812Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

KVD900PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Interested in new trials?

Nivolumab & IpilimumabA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

AtogepantA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Enlicitide DecanoateEnlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

AbeLacimabStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)